CeNeS starts New Year

____________________________________________________________________

10/4/08
CeNeS Pharmaceutical bought by Paion in 10.9 mln pounds all share deal UPDATE

(Adds detail, analyst comment)
LONDON (Thomson Financial) - CeNes Pharmaceutical Plc., a specialty pain
products manufacturer, has agreed to a takeover by German company Paion AG. in a 10.9 million pounds all share deal. The deal values each CeNeS share at 48.9 pence, a 52.7 percent premium on CeNeS closing price of 32 pence on Feb 4. Each CeNeS shareholder will receive 0.3521 Paion shares per CeNeS one.
The combined group should have a combined cash balance of 49 million euro,
with Paion contributing almost all of this.
Neil Clark, CeNeS CEO, said: "The combination creates a diversified pipeline
backed by a strong balance sheet and a proven management team. The enlarged
group will be well-placed to achieve significant clinical and commercial
milestones over the next 24 months."
If the deal is successfully completed, Gavin Kilpatrick, currently CeNeS's
Chief Scientific Officer, will join the management board of Paion, while
Chairman Alan Goodman will sit on the supervisory board.
CeNeS's preliminary results Thursday showed the company to have a cash
balance of only 4.3 million pounds, down from 6.3 million last time and
insufficient to last until the end of the year, while net losses narrowed to 6.6
million pounds from 8.6 million last year.
Jacob Plieth, analyst at Edison Investment Research, said the takeover is "a
strange one because it is not an obvious fit for Paion", although he noted the
price "10.9 million pounds, not even in cash, is a bargain".
CeNeS focuses primarily on pain reduction products, while Paion specialises
mostly in treatments for strokes, which are notoriously hard to treat, and seems
to be well-backed by Danish company Lundbeck AS, he said.
"It is possible Paion are obviously trying to diversify, and I guess they
wanted a bargain that has a Phase III product," Plieth said.
CeNeS has been trying for some time to secure a licensing deal for its lead
M6G post-operative pain product but, according to Plieth, has been hampered by a
possible lack of big Pharma interest - the only significant company which
specialises in pain is Mundy.
The takeover price of around 42 pence appears reasonably low, especially as
the price spiked to 60 pence after takeover talks were announced earlier this
year, Plieth said.
At 9.10, CeNeS shares were 41.5 pence, up 4.5 pence or 12.16 percent, the
pharma sector's second biggest riser.

5/2/08 at 10:11
CeNeS Pharmaceuticals PLC confirmed it is in talks which may or may not lead to an offer for the company, adding that a further announcement will be made in due course.

RNS Number:1796L
CeNeS Pharmaceuticals PLC
07 January 2008

HOLDING IN COMPANY

The Company was informed on 3 January 2008 that Strathclyde Pension Fund had a total interest in 982,620 ordinary shares of 1p each in the capital of the
Company. This shareholding represents 4.48 per cent. of the issued share capital
of the Company.

Cenes Pharmaceutical Trading update

RNS Number:6042C
CeNeS Pharmaceuticals PLC
22 August 2007

Annual General Meeting ("AGM") and
Extraordinary General Meeting ("EGM") Statement

Cambridge, UK, 22 August 2007 - CeNeS Pharmaceuticals plc ("CeNeS" or "the
Company") is holding its AGM and EGM later today.

At the meeting Alan Goodman, the Chairman of CeNeS, will make the following
announcement:

"I am pleased to report that upon the successful conclusion of this meeting
CeNeS will have completed the #6.1m funding that was announced on 27 July 2007.
I would like to thank existing shareholders for their continued support and
welcome new shareholders. Avlar Bioventures, the specialist healthcare fund of
which I am CEO, also supported the funding. The Company is now well funded and
is in a strong position to deliver significant news flow.

"CeNeS' pipeline is focused and well balanced with clearly defined clinical and
commercial targets. The Company is well placed to deliver important data from
its lead programme M6G and also now has an active CNS 5161 Phase II programme
following behind as well as a promising early stage pipeline validated by a
major CNS 7056 partnership with Ono Pharmaceuticals in Japan. It is worth noting
that the Ono deal alone underpins the current market valuation of the company.

"The partnering of our lead programme M6G is proceeding to plan and CeNeS is
confident that it can secure partnering deals in the near future. Since we
announced the clinical data for our Phase III trial in February this year we
have been repeatedly impressed by the depth of evidence that supports the
product profile for M6G of a novel analgesic with a better side effect profile
than morphine. I therefore remain confident that M6G will become a successful
product in the treatment of post-operative pain.

"Our ability to negotiate and complete out-licensing deals has been ably
demonstrated by the deal we have recently secured with Ono Pharmaceuticals for
the Japanese rights to our short acting sedative/anaesthetic CNS 7056. As a
result, we now have a highly regarded Japanese pharmaceutical company working
with us to develop the additional indication of anaesthesia in Japan. In
addition, we are excited about delivering Phase I proof of concept data in 2008
for the indication of sedation and expect this to transform the valuation of
this asset in our pipeline.

"CeNeS is also planning to progress Phase II trials of CNS 5161 in cancer pain
and neuropathic pain in 2007/8 with our development partner Ergomed. Our COMT
inhibitor programme for the treatment of Parkinson's Disease is also moving
forward through the lead optimisation phase as planned.

"As a Board, we look forward to the Company's future with confidence. CeNeS has
a solid balance sheet, a strong Phase III lead programme backed up by good
clinical data, with an active earlier pipeline moving into Phase II and Phase I
trials in the short term. The progress we have made to date and the exciting
news flow ahead means that we are well placed to deliver significantly increased
value to our shareholders."

For more information please contact:
CeNeS Pharmaceuticals plc
Neil Clark, CEO
Tel: +44 (0)1223 266 466

JMFinn Capital Markets
Geoff Nash
Tel: +44 (0)20 7600 1658

Financial Dynamics
Ben Brewerton/Emma Thompson
Tel: + 44 (0) 207 831 3113

About CeNeS Pharmaceuticals

CeNeS is a biopharmaceutical company specialising in the development and
commercialisation of drugs for pain control, sedation and other CNS disorders
such as Parkinson's disease. The company is based in Cambridge, England.

For further information visit the CeNeS website: www.cenes.com


Cenes Pharmaceutical FDA approves IND for M6G
RNS Number:5302V
CeNeS Pharmaceuticals PLC
26 April 2007

CeNeS Pharmaceuticals plc
("CeNeS" or "the Company")
FDA approves IND on Lead Product M6G

Cambridge, UK, 26th April 2007 - CeNeS Pharmaceuticals plc (LSE: CEN), the
Cambridge based biopharmaceutical company, today announces that the United
States Food and Drug Administration (FDA) has approved its Investigational New
Drug (IND) application for the clinical development of morphine-6-glucuronide
(M6G), its novel drug for the treatment of post-operative pain. Earlier this
year, CeNeS announced results of a Phase III study of M6G in Europe in over 500
patients with post-operative pain. The study demonstrated that M6G provided
equivalent pain relief to morphine but induced significantly less post-operative
nausea and vomiting (PONV).

The opening trial under this IND will be a Phase I pharmacokinetic study in
volunteers. This study is required by the FDA as is an additional pre-clinical
toxicology analysis before progressing to Phase III trials. CeNeS is currently
completing the protocol design of the first US Phase III trial. The filing of
the IND enhances the package of data already available to potential US partners
for review.
Neil Clark, Chief Executive of CeNeS, said:

"The FDA's approval of our IND application for M6G is a major landmark in CeNeS
clinical development programme. North America is an attractive market for our
drug candidate and M6G is clearly positioned to be a genuine alternative to
standard morphine therapy."

Cenes Pharmaceutical Clinical Trial Results

RNS Number:5126R
CeNeS Pharmaceuticals PLC
20 February 2007

CeNeS Pharmaceuticals plc
("CeNeS" or "the Company")

Successful Phase III results announced on Lead Product M6G

Phase III trial in Europe demonstrates M6G's benefit compared to morphine in the
treatment of post-operative pain

Cambridge, UK, 20th February 2007 - CeNeS Pharmaceuticals plc (AIM: CEN), the Cambridge based biopharmaceutical company, today announces preliminary results of the pivotal Phase III trial (M6G022) of M6G (morphine-6-glucuronide) in over 500 patients with post-operative pain. This study is the largest carried out to
date with M6G and has delivered very strong results with M6G showing benefits
over morphine in the management of post operative patients. M6G022 demonstrates the unique product profile of M6G with equal analgesia to morphine but with reduced nausea and vomiting.

Phase III trial results

1. M6G matches morphine for analgesic effect Importantly for a novel pain product, the trial results unequivocally show that
M6G is as good as morphine in terms of analgesia achieved in patients up to 48
hours post-operatively. Successful achievement of this first primary endpoint
supports data from previous clinical trials of M6G and is an essential component
in the product profile of M6G.

2. M6G shows significant reduction in post-operative nausea and vomiting
compared to morphine

The trial results confirm the excellent potential of M6G as an analgesic with a
clinically significant improved side effect profile compared to morphine. The
study results show that patients receiving M6G experienced a 28% reduction in
the severity of post-operative nausea and vomiting (PONV) in the key 6 - 24
hours after treatment (statistically significant, p=0.018).

In addition, the incidence of dry retching/vomiting in the M6G arm compared to
the morphine arm in the 24 hour period after treatment was reduced by 32%
(statistically significant, p= 0.044). The incidence and severity of
post-operative nausea in the M6G arm was 27% less than that observed in the
morphine arm in the period 6 - 24 hours after treatment. This was the second
primary endpoint and approached statistical significance (p=0.052).

Morphine formulations are the gold standard treatment for the relief of moderate
to severe post-operative pain. A limitation of morphine treatment is often the
unpleasant side effects experienced, of which nausea and vomiting are the most
common. PONV is rated among patients as one of the most distressing
after-effects of surgery and reduces their quality of life.

M6G's lower propensity to cause nausea and vomiting in the post-operative period
strongly supports CeNeS' belief in the potential of M6G as a novel product for
the treatment of post-operative pain with clear advantages over morphine.

The global market was valued at $1 billion in 2000 and growing at a rate of
6-7%.

3. Safety profile/adverse events

The trial confirmed that M6G's safety profile is similar to morphine. Aside from
nausea and vomiting, the adverse events reported were at levels similar to those
experienced by patients receiving morphine in a post-operative setting.

Dr Alexander Binning M.B. Ch.B. FRCA, Consultant Anaesthetist at Western
Infirmary, Glasgow and Principal Investigator on M6G022, commented: "These data demonstrate that M6G is equivalent to morphine in its analgesic properties. It
also shows a clear improvement in managing post-operative nausea and vomiting
and has significantly advanced the development of M6G as a potential new drug."

Neil Clark, Chief Executive of CeNeS, commented: "These results strongly confirm
our belief in the excellent potential of M6G as a novel product for post
operative pain. The quality and breadth of the data contained in this large
study support M6G's anticipated product profile. With the completion of this
large European study CeNeS is confident that it has a substantial data package
that differentiates M6G from morphine which will be attractive to a larger
pharma partner to licence. CeNeS intends to file an IND (Investigational New
Drug application) for M6G with the FDA in the next few weeks. The data from this
trial will also be submitted for publication in a scientific journal in due
course.

The successful completion of this large, pan-European study demonstrates the
excellence of our clinical development team and the quality of the clinical
trial protocol. Following this success we now look forward to working with
partners to register M6G as a product in major markets."

M6G022 Study Design

The study involved 24 centres in six European countries and recruited 517
patients. The study was designed primarily to provide key information on a
comparison of effective intravenous pain management regimens of M6G or morphine treatment for a minimum of 24 hours (and up to 48 hours) following major
abdominal surgery. Morphine is generally accepted as the "gold standard" drug
for use in these circumstances. Initial pain management was achieved by
administration of a loading dose and titration of either M6G or morphine to
achieve acceptably low levels of pain for the patient to go onto the ward. In
the ward, pain management treatment was achieved by patient controlled analgesia (PCA), whereby the patient was allowed to self administer a dose of M6G or morphine as required to control their pain. The study was randomised and double blind so that neither patient nor carer was aware of which treatment was being administered. The main purpose of the study was to demonstrate statistically that:

- treatment with either M6G or morphine, particularly during PCA, results in
similar levels of pain management; and

- effective analgesic treatment during PCA results in lower levels of nausea and
vomiting in patients receiving M6G compared to those receiving morphine.

In addition, other important side effect, efficacy and safety features were
determined throughout the study.

M6G Commercial Strategy

CeNeS has commissioned a number of qualitative market research studies on M6G, which have been carried out by independent market research agencies with
extensive experience of the pain market. The outcomes of these studies,
involving interviews with clinicians and payers in major markets, support CeNeS'
view that potential global peak sales of M6G in post-operative pain could reach
$400 million. This is underpinned by a clear need for an improvement on existing
drugs for moderate to severe pain which do not offer the attractive M6G profile
of morphine-like pain relief with reduced side effects.

CeNeS believes that the positive results announced today from M6G022 will enable
the Company to secure valuable licensing agreements for Europe and North America with partners able to offer strong specialist marketing, sales and distribution capabilities within the hospital sector. CeNeS intends to explore all
opportunities to capture value from any such licensing agreement including the
possibility of retaining promotion or co-promotion rights within certain
territories.

CeNeS is in discussion with a number of potential partners and is confident that
the positive results from M6G022, together with the extensive package of
clinical, non-clinical and manufacturing data provides an attractive package for
out-licensing.

--ENDS--

There will be a teleconference briefing for analysts and investors today at
9.00am. For details please contact Mo Noonan on +44 (0) 207 831 3113 or
mo.noonan@fd.com.

For more information please contact:
CeNeS Pharmaceuticals plc
Neil Clark, CEO
Tel: +44 (0)1223 266 466

JM Finn
Geoff Nash
Tel: +44(0) 207 628 9688

Financial Dynamics
Ben Brewerton/Emma Thompson
Tel: + 44 (0) 207 831 3113

Interim Results for the six months ended 30 June 2006


CeNeS Pharmaceuticals plc (AIM: CEN), the biopharmaceutical company developing a new generation of pain management products, announces interim results for the six months ended 30 June 2006. In a separate announcement made today, CeNeS gives a more detailed update on its lead product for post-operative pain, M6G.

Highlights

Clinical pipeline

M6G - morphine-6-glucuronide
* Recruitment in M6G pivotal Phase III study for post-operative pain
nearing completion
* Successful pre-IND meeting with FDA clarifies US Phase III clinical
trials plan

CNS 5161
* Successful progression of development strategy for CeNeS second clinical
compound CNS 5161
* CeNeS and ERGOMED sign Revenue Sharing and Co-Development agreement for CNS 5161 under which two Phase II pain studies are planned to complete in 2007
* Acquisition of transdermal patch formulation IP relating to CNS 5161
from Alza Corporation enabling development of high value transdermal
formulation of CNS 5161 for neuropathic pain
* Encouraging Phase IIa clinical data on CNS 5161 for diabetic neuropathic
pain presented at European Association for the Study of Diabetes (EASD)
conference

Pre-clinical/discovery pipeline

CNS 7056 - short acting sedation/anaesthesia
* Japanese and European patents granted for short acting sedative CNS 7056
* Encouraging pre-clinical studies reveal rapid onset and offset of
sedative action and rapid metabolism and also support the potential to
expand indications for CNS 7056 into anaesthesia
* Further studies in anaesthesia initiated at The University of Adelaide
and under a Material Transfer Agreement with a major pharmaceutical company

COMT inhibitors - Parkinson's
* Pre-clinical development candidate for Parkinson's on plan to be
selected from lead series in 2006

Corporate
* Scientific Advisory Board (SAB) strengthened
* Further progress in portfolio of carried interests

Financial
* Increased net loss after tax for the first half of 2006 of #4.1 million
(H1 2005: #3.1 million) due to planned increase in clinical development
activities
* Cash and short term investments at period end of #5.4 million (June
2005: #11.5 million)

Alan Goodman, Chairman of CeNeS Pharmaceuticals said:

"CeNeS is entering a very exciting period of news flow in the coming months.
Results from the pivotal Phase III trial of M6G will be a major breakthrough for
CeNeS, if successful. M6G has the potential to be a major new pain drug with a
unique profile that will assist patients and physicians alike in the successful
management of post-operative pain.

We also have a number of high quality programmes that are all well positioned to
deliver clear proof of concept data in the next 12 months and which will, if
successful, add significant value to the Company. We are also encouraged by the
interest in our late and early stage programmes from potential partners. The
Board is increasingly confident in the immediate outlook and the longer term
future of the Company."

Clinical programmes

Good progress has been made in advancing the clinical and pre-clinical pipeline
and we are entering a very exciting period of news flow, with the next major
event being the announcement of results from our pivotal Phase III study testing
our lead programme M6G against the gold standard morphine treatment for
post-operative pain.

M6G

M6G continues to progress through its pivotal Phase III trial in Europe.
Recruitment should complete in the next two months, with results reported
shortly after, and we are confident that this will demonstrate clearly the
planned benefits of M6G as compared to morphine in the treatment of moderate to
severe post-operative pain. A successful result will enable us to finalise our
partnering plans in Europe and provide a key trigger to the next stage of CeNeS
corporate strategy. For a more detailed update on CeNeS lead candidate M6G
please see today's other press release.

Our market research and discussions with a wide range of pain specialists
supports our view that there is a clear clinical and commercial opportunity for
a new opiate pain drug that has similar pain relieving properties to morphine
but a better side effect profile. Our current Phase III trial is testing that
exact principle in patients who have had abdominal surgery and who are
experiencing moderate to severe post-operative pain.

Our pre-IND meeting in July 2006 with the FDA has greatly clarified the clinical
trials work necessary in the United States. We are confident that success in the
ongoing European Phase III trial, in combination with the IND we are planning to
file by the end of 2006, will provide an attractive clinical data package which
will enhance the value of our North American partnering opportunities.

CeNeS has worked with independent third parties to build a robust market model
which supports our estimate that the potential global peak sales of M6G in
post-operative pain could reach #200 million per annum. In addition, if M6G
proves to be a success in the intravenous post-operative pain market there is
significant potential to develop new formulations for other segments of the pain
market.

CNS 5161

Our second clinical candidate is CNS 5161. This compound has demonstrated
efficacy and an acceptable side effect profile in two Phase IIa proof of concept
studies in neuropathic pain patients. In July 2006 CeNeS entered a major
co-development partnership with Ergomed, an experienced clinical development
company specialising in neurology and oncology clinical trial design and
management, and larger Phase II studies planned for 2007 will investigate the
clinical effects of CNS 5161 in diabetic neuropathic pain patients. CeNeS and
Ergomed plan to complete a double-blind, 3-way cross-over, acute study to
compare the efficacy and safety of two doses of CNS 5161 (250ug and 500ug) and
placebo in 75 diabetic neuropathy patients with chronic, intractable neuropathic
pain. Diabetic neuropathic pain is a condition which is increasing in prevalence
in line with the increase in the incidence of diabetes. It is estimated that
half of diabetic sufferers develop some form of neuropathic pain. Drug
treatments for neuropathic pain represent a significant area of unmet medical
need and a growing market opportunity that is currently valued at over $2
billion globally and is forecast to reach $5 billion by 2010.

Additionally, CeNeS plans to complete a trial in opioid refractory cancer pain.
The study will be a Phase I/II dose-escalation study in 24 patients to establish
the optimal schedule for infusion of CNS 5161 in the management of cancer pain.
Patient recruitment in both studies is expected to start in early 2007 and
complete later that year.

Also in July 2006 CeNeS completed the assignment of transdermal patch technology
from Alza. CeNeS has already produced preliminary data demonstrating feasibility
for a transdermal patch formulation of CNS 5161 and the assignment will enable
formulation development to be carried out in parallel to the Phase II studies.
CeNeS already possesses composition of matter per se patents on CNS 5161, and
patent protection may be extended to 2020 through the acquisition of this
intellectual property.

Pre-clinical programmes

CNS 7056

CNS 7056 is the lead compound of a series that was assigned to CeNeS from
GlaxoSmithKline in November 2003. Pre-clinical development work is ongoing with
the intention of filing an IND in the US and then conducting a first proof of
concept Phase I study in 2007. The United States is a major potential market for
short acting sedatives.

Data to be presented at scientific meetings later in 2006 will highlight the
very encouraging pre-clinical profile of CNS 7056, including new results showing
a rapid onset and offset of sedative action and rapid metabolism by human liver
samples. The compound is being developed primarily as a sedative for short
non-surgical and surgical procedures. In addition, on the basis of these new
data, CeNeS is now evaluating the potential of CNS 7056 for use in the induction
and maintenance of anaesthesia. Pre-clinical studies to evaluate the potential
of CNS 7056 in these additional indications are being undertaken at The
University of Adelaide and under a Material Transfer Agreement at a major
pharmaceutical company. The evaluation will complete in the second half of 2006.
Extending the development of CNS 7056 to include the induction and maintenance
of anaesthesia could double the estimated potential market opportunity to over
#400 million.

COMT Inhibitor

CeNeS COMT inhibitor discovery programme has succeeded in identifying several
series of novel active compounds, thereby achieving a chemical breakaway from
currently marketed COMT inhibitors. CeNeS is developing these lead series with a
view to further optimising in vitro and in vivo activity as well as their ADMET
(absorption, distribution, excretion, metabolism and toxicity) profile, thus
addressing the known limitations associated with existing marketed therapies.
The programme has continued to perform to plan and the Company expects to select a development candidate from the lead series in 2006. CeNeS is excited about its potential to deliver improved therapies for the treatment of Parkinson's
disease.

Update on portfolio of carried interests

CeNeS has a portfolio of carried interests arising for non-core assets which
were disposed during the 2001 restructuring programme. In September 2006 Addex
Pharmaceuticals Limited ("Addex") has completed a venture capital funding
raising Euro25 million. Addex has announced that its programme ADX10061, a dopamine
D1-selective antagonist, is expected to commence a Phase II smoking cessation
study in the US in the coming months. CeNeS licensed out this dopamine
D1-selective antagonist to Addex in December 2002 and CeNeS could potentially
receive up to $4.5 million in milestones and royalties in stages over the next
few years if the programme progresses successfully through clinical development.

A summary of CeNeS carried interests is set out below. In the longer term, the
Board believes this portfolio could generate up to $20 million plus royalty
streams if various milestones and targets are achieved under the agreed
contracts.


Asset disposed New owner/ CeNeS carried interest *
partner

Ion channel library Wyeth Stage payments and milestones
Pharmaceuticals

GGF2 - potential treatment for Acorda Milestones and royalties
multiple sclerosis Therapeutics,
Inc

CEE 03 310 - dopamine Addex Milestones and royalties
D1-selective antagonist. Pharmaceuticals
Potential treatment for sleep SA
disorders and substance abuse

Cognitive testing division Cambridge Milestone payment
Cognition
Limited

AutoPatch technology and Xention Minority shareholding, loan note
certain ion channel assets Discovery and certain rights over
Limited potential pain drug candidates
arising from Xention's work


*The receipt of future milestones and/or royalties is dependent on the
successful progression of the divested asset/technology and as such is not
certain.

Corporate

The Company is pleased to have appointed Professor Robert Sneyd (Associate Dean
and Professor of Anaesthesia, Peninsula Medical School, University of Plymouth,
UK) and Professor Peter Glass (Professor and Chairman, Department of
Anesthesiology, Stony Brook University Hospital, USA) to the Scientific Advisory
Board. With their recognised expertise in anaesthesia and pain, they will aid
the existing SAB in providing excellent support to our drug development
programmes.






30 June 2005
CeNeS Pharmaceuticals plc ('the Company')
Director's shareholding
The Company was informed today that Mr Alan Goodman, Chairman of the Company, purchased 500,000 ordinary shares of 1p each in the Company at a price of 7.875 pence per share. Following this purchase Mr Goodman has a beneficial interest in 15,343,866 ordinary shares representing 3.7% of the Company's total issued share capital.

Holding in Company

The Company announces that on 29 June 2005 it received notification from Mr R G
Robb Esq. that he has a notifiable interest in 17,000,000 Ordinary Shares of 1p
each in the Company, representing approximately 4.1% of the Company's issued
ordinary share capital. This shareholding is registered in the name Hanover
Nominees Limited.


CeNeS and Tripos Announce Advances in COMT inhibitor discovery programme

Cambridge, U.K. and St. Louis, USA, 13 April 2005 - CeNeS Pharmaceuticals
("CeNeS", AIM:CEN) the Cambridge-based biopharmaceutical company, and Tripos ("Tripos", Nasdaq: TRPS), a leading global provider of drug discovery chemistry and informatics solutions, today announced that they have reached important milestones in their joint research partnership on COMT inhibitors and have consequently entered into a new agreement to continue their collaboration.
Terms of the agreements were not disclosed.

Following on from CeNeS' innovative research programme that commenced in 2003, the two companies have been working together and have identified several series of novel compounds active against the clinically validated target
catechol-O-methyltransferase (COMT). COMT inhibitors are currently used
clinically for adjunct therapy in Parkinson's disease since they prolong the
effects of the dopamine precursor L-DOPA. CeNeS first identified an opportunity
to improve on current drugs in 2002 and has been working with Tripos to design
novel COMT inhibitors that may have significant improvements over existing
treatments.

As part of the ongoing collaboration, Tripos Discovery Research is using its
knowledge-driven chemistry process to facilitate rapid lead identification,
follow-up and chemical optimization of candidate molecules. Building on CeNeS'
proprietary information coupled with CeNeS' internal chemical design platform,
Tripos uses structure-based design tools to investigate the interaction of
proposed leads with the validated target. Novel compounds have been selected
for synthesis and screened for biological activity. The new project will
involve the optimization of these active compounds.

In addition, new genetic data has recently been published implicating a genetic
link between the high activity form of the COMT enzyme with a predisposition to
develop drug-induced psychosis. Caspi et al.,1 as noted in The Times (London,
UK, Tuesday 12 April 2005), observed that one in four people carries the high
activity version of the COMT gene and that possession of this variant gene
increases the vulnerability to psychotic illnesses by about 5-fold in
adolescents that smoke cannabis.

Continuing the association between COMT and psychosis, recent work2, most
notably from Professor Daniel Weinberger's group based at the National
Institute of Mental Health (NIMH, Bethesda, USA), has provided strong evidence
supporting the hypothesis that a COMT inhibitor that acts in the brain would be
a useful agent to tackle the profound cognitive deficits in schizophrenia.

"CeNeS' strategy is to develop novel products that reduce the risks inherent in
drug development by focusing on known mechanisms and established clinical
targets. Two COMT inhibitors are marketed currently. One does not enter the
brain effectively and the other is associated with serious liver toxicity. Our
goal is to identify compounds without these deficits." said Neil Clark, CeNeS
Chief Executive Officer.

"The COMT discovery program is a good example of our strategy in progress,"
said Dr. Gary Tilbrook, CeNeS Chemistry Director. "CeNeS is excited about this
discovery programme's potential to deliver improved drugs for the treatment of
Parkinson's disease. The important recent data also shows that our COMT
inhibitors may have therapeutic utility in psychotic disorders including
schizophrenia."

ENDS

1 Moderation of the effect of adolescent-onset cannabis use on adult psychosis
by a functional polymorphism in the catechol-O-methyl transferase gene:
longitudinal evidence of a gene X environment interaction. Caspi et al.,
Biological Psychiatry. In Press 2005.

2 Presented at the Society for Neuroscience (San Diego, USA, November 2004) and
the American College of NeuroPsychopharmacology (Puerto Rico, December 2004)
meetings.

For more information please contact:

CeNeS Pharmaceuticals plc
Neil Clark
Tel: +44 (0)1223 266466
Fax: +44 (0)1223 266467

Northbank Communications
Emma Palmer
Douglas Pretsell
Tel: +44 (0)20 7886 8150

Tripos, Inc.
Jim Rubin
Chief Financial Officer
(314) 647-1099

Waggener Edstrom Bioscience
Lisa Osborne
Account Supervisor
(425) 638-7000
lisao@wagged.com

About CeNeS

CeNeS (CEN.L) is a biopharmaceutical company specialising in the development
and commercialisation of drugs for pain control, sedation and other CNS
disorders such as Parkinson's disease. The company is based in Cambridge,
England. For further information visit www.cenes.com.

About Tripos

Tripos (Nasdaq: TRPS) combines cutting-edge technology and innovative science
to deliver leading chemistry-research products and services for the
biotechnology, pharmaceutical and other life science industries. Headquartered
in St. Louis, Mo., Tripos spans the world with global research operations and
an international client base. www.tripos.com

About Parkinson's disease

Parkinson's disease is the second most common neurodegenerative disease after
Alzheimer's disease. It affects approximately 2 per cent of the population over
the age of 65, representing approximately 4 million patients worldwide.

Parkinson's disease results from a loss of the neurotransmitter dopamine in the
brain. Replacement therapy using L-DOPA, the precursor of dopamine, is the main
treatment for Parkinson's disease. However, L-DOPA is quickly metabolised in
the gut and liver allowing only a small proportion (approximately one per cent)
to reach the brain. Therefore, L-DOPA is formulated with agents that inhibit
the breakdown of L-DOPA by DOPA-decarboxylase, such as carbidopa and
benserazide. The Directors anticipate that L-DOPA therapy will continue to be
the `gold standard' treatment for the foreseeable future.

After prolonged use, the beneficial effects of L-DOPA become reduced and
patients develop motor fluctuations and dyskinesias. These probably represent
the biggest single problem in the long-term management of a patient with
Parkinson's disease.

The enzyme catechol-O-methyl transferase ("COMT") also causes significant
depletion of L-DOPA in the brain and periphery, limiting the efficacy of L-DOPA
replacement therapy.

The global market for drugs targeting Parkinson's disease was $1.7 billion in
2003 and is forecast to grow substantially over the next decade with an
increased prevalence of the disease as a consequence of the ageing population.
COMT inhibitors currently have a 10% share of the Parkinson's disease market by
value and their usage is growing

About Schizophrenia

Schizophrenia is a debilitating mental illness characterized by disturbances
such as hallucinations and delusions as well as a range of negative symptoms,
including cognitive disturbances. Cognitive disturbances often prevent
schizophrenia patients from readjusting to society and require patients to be
under medical care for their entire lives. Despite the availability of a
variety of current antipsychotic drugs with worldwide sales exceeding USD $12
billion, cognitive disturbances are poorly addressed by existing therapies and
represent a large unmet medical need in schizophrenia therapy.

About Drug-Induced Psychosis

Use of cannabis or other drugs can cause a condition known as drug-induced
psychosis. Symptoms usually appear quickly and last a relatively short time (a
few days) until the effects of the cannabis wear off. Disorientation, memory
problems and visual hallucinations are the most common symptoms. If someone has
a predisposition to a psychotic illness, such as schizophrenia, use of drugs
such as cannabis may trigger the first episode in what can be a lifelong,
disabling condition.
END